Research · Sep 3, 2026
AbbVie FY25 (Dec 31, 2025) at $61.2B net revenue (+8.6%). Skyrizi $17.6B (+50%), Rinvoq $8.3B (+39%), Humira $4.5B (-50% Y3 LOE). Combined S+R $25.9B vs Humira FY23 $14.4B — bridge confirmed. GAAP net income $4.2B (heavy intangibles amortization); OCF $19.0B; FCF $17.8B. Capital return $12.7B (div $11.7B + buyback $1.0B); net debt $63.8B (Allergan/Cerevel deleveraging priority). 10 analysts: 8 Buy / 2 Hold; consensus $253.80, range $228-$294.
Research · Aug 25, 2026
Kura and Syndax each report about 40% of menin inhibitor use in physician-led combinations, moving the revenue variable to treatment duration rather than the label.
Research · Aug 25, 2026
Sisram, AbbVie and Evolus told investors injectable aesthetics is now priced by how long an effect lasts: Juvederm fell 6.6% while DAXXIFY holds RMB6,800.
Research · Jun 9, 2026
Biotech M&A 2026 on track for best year since 2018. Patent cliffs (Keytruda 2028, Trulicity 2027) drive LLY/MRK/PFE acquisition urgency.
Research · Apr 13, 2026
Trump policies eroding Europe's pharma lead via tariffs favor US manufacturing-heavy Eli Lilly and Amgen, with strong growth and margins, while Pfizer and Merck's global chains invite cost squeezes. J&J and AbbVie sit in the middle with diversification. Rank: Buy LLY/AMGN, sell PFE/MRK.
Research · Apr 10, 2026
Trump's pharma import tariffs shield U.S.-focused drugmakers like Eli Lilly and Amgen from cost hikes while pressuring import-reliant Pfizer and Merck. Analysis ranks six majors by exposure, highlighting financials and guidance. Domestic winners eye margin expansion amid onshoring push.
